Brief: Arcutis Enrolls First Child In INTEGUMENT-INFANT Evaluating ZORYVE Cream 0.05% In Infants With Atopic Dermatitis
10/06/2025 13:58
June 10 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS ENROLLS FIRST CHILD IN INTEGUMENT-INFANT EVALUATING ZORYVE® (ROFLUMILAST) CREAM 0.05% IN INFANTS WITH ATOPIC DERMATITIS Source text: ID:nGNXb4GXn7 Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf